EFFECT OF CITRUS FLAVONOIDs AND TOCOTRIENOLs ON SERUM CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC SUBJECTS

James M. Roza, CN; Zheng Xian-Liu, PhD; Najla Guthrie

Context • Preliminary studies have suggested that both citrus flavonoids and palm tocotrienols reduce cholesterol levels in laboratory animals.

Objective • To examine the effect of these nutrients in combination on blood levels of cholesterol and related cardiovascular disease risk factors.

Design • Two open-label studies and 1 double-blind study are reported.

Setting • Outpatient clinical research setting.

Patients • Three groups (n=10, n=10, n=120) of hypercholesterolemic men and women (cholesterol levels >230 mg/dL) between the ages of 19 and 65 years were recruited.

Intervention • Subjects were randomized to consume either 270 mg citrus flavonoids plus 30 mg tocotrienols (S) or placebo (P) daily for a period of 4 weeks (group 1 [G1] and group 2 [G2]) or 12 weeks (group 3 [G3]).

Main Outcome Measures • Measurements of fasting levels of blood cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides were made at baseline and 4 weeks (all groups) and at 8 weeks and 12 weeks (G3).

Results • Daily treatment with S significantly improved cardiovascular parameters compared to P in all groups. Significant reductions were shown in total cholesterol (20%-30%), LDL (19%-27%), apolipoprotein B (21%), and triglycerides (24%-34%). HDL levels remained unchanged in G1 and G2 but increased 4% (nonsignificant) in G3 and was accompanied by a significant increase in apolipoprotein A1 (5%). (Altern Ther Health Med. 2007;13(6):44-48.)

James M. Roza, CN, is a certified nutritionist and vice president of Science and Technology, SourceOne Global Partners, Chicago, Illinois; Zheng Xian-Liu, PhD, is a consultant and chief executive officer of Geronutra, Haywood, California; and Najla Guthrie is chief executive officer of KGK Synergize, London, Ontario.

DISCLOSURE
The work was funded by KGK Synergize, London, Ontario, and performed at the Universities of Guelph and Western Ontario. Roza is an employee of SourceOne Global Partners, which distributes polymethoxyflavones and tocotrienols. Liu served as a paid consultant to SourceOne in the preparation of this manuscript but holds no other financial interest in the extracts studied or in either KGK Synergize or SourceOne. Guthrie is president/chief executive officer of KGK Synergize and holds patents related to the use of the studied extracts for cardiovascular disease.

Cardiovascular disease is the number one cause of death in America. According to the American Heart Association, approximately 20% of Americans have high blood cholesterol. Lowering blood cholesterol is an advised strategy to help reduce the risk of cardiovascular disease. The National Heart, Lung, and Blood Institute recently revised their guidelines for healthy cholesterol and triglyceride levels for the US population (Table 1). By lowering the cut-off point for total and low-density lipoprotein (LDL) cholesterol, these recommendations suggest a need for greater focus by the US population on reducing and maintaining healthy cholesterol and triglyceride levels.

A number of epidemiological studies provide evidence that consumption of fruit and vegetables is associated with reduced risk of cardiovascular disease. This cardioprotective effect is thought to be due, at least in part, to minor components of fruit and vegetables called flavonoids. Previous studies have shown that flavonoids and limonoids from citrus, as well as unextracted citrus juices, have cholesterol-lowering properties. In a human liver cell line (HepG2), principal flavonones from oranges and grapefruit, hesperetin and naringenin, both reduced the medium content of apolipoprotein B, the main protein component of LDL, with IC₅₀ concentrations 43.0 and 48.5 mg/mL medium, respectively. A more pronounced reduction of medium apolipoprotein B in HepG2 cells has been observed for a principal citrus limonoid, limonin (IC₅₀ 20.5 mg/mL), and especially for polymethoxyflavones (PMFs) from tangerines, tangeretin (IC₅₀ 2.5 mg/mL). In animal experiments, citrus flavonoids alone or in combination with limonoids also produced hypolipidemic responses in vivo. In hamsters fed a hypercholesterolemic diet for 5 weeks, dietary supplementation with 0.1%-1% citrus PMFs containing...
Citrus Flavonoids and Tocotrienols for Hypercholesterolemia

To tocotrienols reduce medium content of apolipoprotein B. The evidence for the cholesterol-lowering effect of tocotrienols in humans is less clear, with some trials showing a significant reduction of LDL cholesterol and related cardiovascular risk factors and others showing no effect. Tocotrienols, like PMFs, have been shown to produce cardioprotective effects beyond their lipid-lowering action. They are known to have strong antioxidant properties and therefore may protect LDL from oxidation and subsequent formation of atherosclerotic plaque. Recent reports have demonstrated that dietary tocotrienol supplements prevent development of high blood pressure in rats and that the ability of tocotrienols to prevent formation of atherosclerotic lesions may be via inhibition of monocyte adherence to the vascular endothelium.

OBJECTIVE
In this study, we assessed the cholesterol-reducing effects of a combination of PMFs (270 mg/d) and tocotrienols (30 mg/d) in 3 groups of hypercholesterolemic subjects. The selection of this combination was based on previous in vitro and in vivo research that demonstrated its effectiveness in improving lipid profiles.

PARTICIPANTS
Male and female adults between the ages of 19 and 65 years were recruited and provided informed consent. All work was done at the Universities of Guelph and Western Ontario in accordance with ethical treatment of human subjects in clinical research. Inclusion criteria called for total cholesterol levels above 230 mg/dL and LDL >155 mg/dL. Subjects were asked to limit alcohol intake to no more than 2 drinks per day, and alcohol consumption was monitored at each visit. All subjects had to be statin-free prior to participating. Those on cholesterol-lowering medications were required to undergo a 6-week washout period prior to supplementation.

Three groups of subjects were recruited through the use of advertisements and referrals made by general practitioners.

<table>
<thead>
<tr>
<th>TABLE 2 Participant Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
</tr>
<tr>
<td>(n=10,</td>
</tr>
<tr>
<td>6 males,</td>
</tr>
<tr>
<td>4 females</td>
</tr>
<tr>
<td>Age (y)</td>
</tr>
<tr>
<td>Height (cm)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
</tr>
</tbody>
</table>

* S indicates 270 mg citrus flavonoids plus 30 mg tocotrienols; P indicates placebo.
Participant characteristics are listed in Table 2. Participants in group 1 (n=10) and group 2 (n=10) received the supplement combination in an open-label fashion. Participants in group 3 (n=120) were randomized to receive either the supplement combination or a matching placebo in double-blind fashion. Participants in group 3 were part of a larger crossover design study that is ongoing. The first phase is reported here, with the full study results to follow in a future report. A dietary questionnaire was not included as part of this study but will be used in future investigations.

**DESIGN/METHODS**

Participants were asked to consume a combination of PMFs (270 mg/d) and tocotrienols (30 mg/d) (S) or a placebo (P) for 12 weeks (150 mg BID). Following informed consent and practical instructions on how to include supplements in a normal diet, blood samples (30 mL) were obtained from a forearm vein at baseline (all groups), week 4 (all groups), week 8 (group 3), and week 12 (group 3) after fasting. Total and HDL cholesterol and triglycerides were measured in whole plasma using enzymatic timed-endpoint methods (Cholesterol Kit K603-100, BioVision, Mountain View, California) in the Clinical Biochemistry Laboratory of the London Health Science Centre. The concentration of LDL cholesterol was calculated. Plasma concentrations of apolipoprotein B and apolipoprotein A1 were analyzed immunonephelometrically (BNII System, Dada-Behring Canada Inc, Mississauga, Ontario, Canada).

Statistical analysis was by analysis of variance with Dunnett’s post-test. Data are reported as mean ± standard deviation.

**SAFETY/MAXIMUM TOLERATED DOSE**

Prior to the PMF and tocotrienol group studies, an animal study was conducted to evaluate the highest effective dose of a combination of PMFs and tocotrienols. Three groups (n=3) of mice were fed semi-purified diet containing 5% corn oil and a combination of PMFs and tocotrienols at 4 different levels (0.5%, 1.0%, 2.0%, and 4.0%). The animals were followed for 5 weeks and observed for signs of toxicity, such as weight loss and inactivity. For each group, all animals were necropsied at termination, and tissues were examined grossly under a dissecting microscope for abnormalities. Liver, spleen, and kidney sections were examined histologically for signs of toxicity. Body weight, food consumption, and histological results indicate that the maximum tolerated dose of the supplement in the diet is 1.0%.

**RESULTS**

In group 1, 4 weeks of open-label treatment with the supplement combination resulted in a significant reduction in levels of total cholesterol (-25%), LDL cholesterol (-19%), and triglycerides (-24%). HDL levels were unchanged (Table 3, Figure 1).

In group 2, 4 weeks of open-label treatment with the supplement combination resulted in significant reductions in total cholesterol (-20%), LDL (-22%), apolipoprotein B, an important structural protein of LDL (-21%), and triglycerides (-28%). Additionally, subjects in group 2 showed a significant 5% increase in apolipoprotein A1, an important structural protein of HDL, but no significant change in HDL levels (Table 3, Figure 1).

In group 3, 12 weeks of double-blind, placebo-controlled treatment resulted in significant reductions in total cholesterol (-30%), LDL (-27%), and triglycerides (-34%). In addition, HDL levels increased 4% (ns), resulting in a 29% improvement in the LDL:HDL ratio (Table 4, Figure 1).

**CONCLUSIONS**

Approximately 80% of the body’s cholesterol is produced by the liver. As a result, many patients find that attention to diet and exercise are not enough to keep cholesterol levels in a healthy range. This has led to a dramatic increase in prescriptions for drugs known as statins (eg, HMG-CoA reductase inhibitors). Statins are effective at lowering total cholesterol and LDL cholesterol levels, but they have been associated with certain negative side effects, including muscle and liver damage. Statins are also known to reduce tissue levels of coenzyme Q10—a crucial cofactor for heart muscle contractile function. Disillusioned

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>266.82 ± 34.80</td>
<td>201.08 ± 27.07†</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>181.75 ± 30.94</td>
<td>146.95 ± 27.07†</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>42.54 ± 11.60</td>
<td>42.54 ± 11.60</td>
</tr>
<tr>
<td>Total triglycerides (mg/dL)</td>
<td>96.68 ± 19.34</td>
<td>73.47 ± 19.34†</td>
</tr>
<tr>
<td>Apo A1 (g/L)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Apo B (g/L)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*LDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Apo A1, apolipoprotein A1; Apo B, apolipoprotein B; N/A, not applicable. (Significantly different between baseline (pre) and week 4 (post)).
with some of these potential side effects and the high cost of statins, cholesterol-conscious consumers are increasingly looking for alternatives.

PMFs are a subclass of citrus bioflavonoids, including nobiletin and tangeretin, that are distinguished by an extra methyl group. Both nobiletin and tangeretin have been studied for their anti-inflammatory and hypocholesterolemic effects. Mechanistic studies have shown these PMFs to lower LDL levels by inhibiting the synthesis of both apolipoprotein B and triglycerides. Apolipoprotein B and triglycerides are considered to be primary “building blocks” of the LDL particle, with apolipoprotein B making up almost 90% of the LDL cholesterol complex.

Palm tocotrienols are extracted from the fruit of the palm tree nut and are naturally occurring antioxidant analogs of tocopherols, a family of nutrients that includes natural Vitamin E. Tocotrienols are known to possess potent antioxidant and anti-inflammatory activity. In addition, tocotrienols are known to regulate cholesterol production and exert a potent hypocholesterolemic effect via suppression of the HMG-CoA reductase enzyme. Unlike statin drugs, which reduce the activity of the HMG-CoA reductase enzyme, however, tocotrienols appear to reduce total and LDL cholesterol levels by a novel post-transcriptional mechanism that regulates the degradation rate of the HMG-CoA reductase enzyme.

Other studies have demonstrated the antioxidant and anti-inflammatory benefits of PMFs and tocotrienols, and when combined with the current findings of a significant and repeatable reduction of total cholesterol, LDL cholesterol, and triglycerides, they lend further support to the overall cardioprotective benefits of these natural extracts. The results from this series of studies and others show that this combination of citrus PMFs plus palm tocotrienols is a promising natural option for controlling cholesterol and related cardiovascular risk factors in patients with elevated cholesterol levels. Integrative-minded physicians and allied healthcare practitioners should consider this combination of fruit extracts to be a safe and efficacious option for promoting cardiovascular wellness.

REFERENCES


**TABLE 4** Placebo-Controlled Group (Group 3)—Changes in Cholesterol and Triglyceride Levels After 12 Weeks of Supplementation*

<table>
<thead>
<tr>
<th>Measure</th>
<th>Treatment</th>
<th>Baseline</th>
<th>4 weeks</th>
<th>8 weeks</th>
<th>12 weeks</th>
<th>Δ 0-12 weeks</th>
<th>% change from P</th>
<th>% change within group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>P</td>
<td>287±33</td>
<td>297±36</td>
<td>293±32</td>
<td>295±34</td>
<td>8</td>
<td>-30%†</td>
<td>-27%‡</td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>293±32</td>
<td>219±31</td>
<td>216±32</td>
<td>215±34</td>
<td>-78</td>
<td>-27% †</td>
<td>-25%‡</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>P</td>
<td>204±32</td>
<td>209±33</td>
<td>206±34</td>
<td>207±33</td>
<td>3</td>
<td>-1.7%</td>
<td>-25%‡</td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>208±27</td>
<td>161±29</td>
<td>159±31</td>
<td>156±30</td>
<td>-52</td>
<td>-27% †</td>
<td>-25%‡</td>
</tr>
<tr>
<td>Total triglycerides (mg/dL)</td>
<td>P</td>
<td>104±19</td>
<td>105±19</td>
<td>106±20</td>
<td>107±19</td>
<td>3</td>
<td>-34%‡</td>
<td>-31%‡</td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>105±19</td>
<td>74±17</td>
<td>71±17</td>
<td>73±18</td>
<td>-32</td>
<td>-34%‡</td>
<td>-31%‡</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>P</td>
<td>45±10</td>
<td>44±10</td>
<td>45±10</td>
<td>45±10</td>
<td>NC</td>
<td>NC</td>
<td>NC</td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>43±11</td>
<td>45±11</td>
<td>44±12</td>
<td>45±12</td>
<td>2</td>
<td>4%</td>
<td>+4%</td>
</tr>
<tr>
<td>LDL:HD ratio</td>
<td>P</td>
<td>4.53</td>
<td>4.75</td>
<td>4.58</td>
<td>4.60</td>
<td>0.07</td>
<td>+1.7%</td>
<td>+1.7%</td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>4.84</td>
<td>3.58</td>
<td>3.61</td>
<td>3.47</td>
<td>-1.37</td>
<td>-30%‡</td>
<td>-28%‡</td>
</tr>
</tbody>
</table>

*P indicates placebo; S, supplement; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; NC, no change from baseline; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
†Significantly different from placebo, P≤.05.
‡Significantly different within same group, P≤.05.


